van der Merwe N, Buccimazza I, Rossouw B, Araujo M, Ntaita K, Schoeman M
Breast Cancer Res Treat. 2024; 207(2):331-342.
PMID: 38814507
PMC: 11297091.
DOI: 10.1007/s10549-024-07362-2.
Iwai Y, Toumbou K, Zuze T, Morgan J, Simwinga L, Wright S
JCO Glob Oncol. 2023; 9:e2300154.
PMID: 37944088
PMC: 10645409.
DOI: 10.1200/GO.23.00154.
van der Merwe N, Ntaita K, Stofberg H, Combrink H, Oosthuizen J, Kotze M
Front Oncol. 2022; 12:938561.
PMID: 36568162
PMC: 9768488.
DOI: 10.3389/fonc.2022.938561.
van der Merwe N, Combrink H, Ntaita K, Oosthuizen J
Front Genet. 2022; 13:834265.
PMID: 35464868
PMC: 9024354.
DOI: 10.3389/fgene.2022.834265.
ElBiad O, Laraqui A, El Boukhrissi F, Mounjid C, Lamsisi M, Bajjou T
BMC Cancer. 2022; 22(1):208.
PMID: 35216584
PMC: 8876448.
DOI: 10.1186/s12885-022-09181-4.
New Insights Into c.815_824dup Pathogenic Variant of in Inherited Breast Cancer: A Founder Mutation of West African Origin.
Diop J, Sene A, Dia Y, Ba S, Mbacke S, Ly C
Front Oncol. 2022; 11:810060.
PMID: 35096615
PMC: 8793276.
DOI: 10.3389/fonc.2021.810060.
Pioneering Point-Of-Care Testing for Integration of Germline and Tumor Genetics in Breast Cancer Risk Management: A Vision for the Future of Translational Pharmacogenomics.
Mampunye L, van der Merwe N, Grant K, Peeters A, Torrorey-Sawe R, French D
Front Oncol. 2021; 11:619817.
PMID: 34660253
PMC: 8513538.
DOI: 10.3389/fonc.2021.619817.
Identification of :c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients.
Li J, Han S, Zhang C, Luo Y, Wang L, Wang P
Front Oncol. 2021; 11:655709.
PMID: 34046351
PMC: 8148338.
DOI: 10.3389/fonc.2021.655709.
Mutation Detection in the Tumor Tissue from Selected Polish Patients with Breast Cancer Using Next Generation Sequencing.
Szczerba E, Kaminska K, Mierzwa T, Misiek M, Kowalewski J, Lewandowska M
Genes (Basel). 2021; 12(4).
PMID: 33918338
PMC: 8065856.
DOI: 10.3390/genes12040519.
A Review of Cancer Genetics and Genomics Studies in Africa.
Rotimi S, Rotimi O, Salhia B
Front Oncol. 2021; 10:606400.
PMID: 33659210
PMC: 7917259.
DOI: 10.3389/fonc.2020.606400.
Breast cancer in low-middle income countries: abnormality in splicing and lack of targeted treatment options.
Francies F, Hull R, Khanyile R, Dlamini Z
Am J Cancer Res. 2020; 10(5):1568-1591.
PMID: 32509398
PMC: 7269781.
The contribution of large genomic rearrangements in BRCA1 and BRCA2 to South African familial breast cancer.
van der Merwe N, Oosthuizen J, Theron M, Chong G, Foulkes W
BMC Cancer. 2020; 20(1):391.
PMID: 32375709
PMC: 7203887.
DOI: 10.1186/s12885-020-06917-y.
Analysis of Heterozygous BRCA1 5382ins Founder Mutation in a Cohort of Egyptian Breast Cancer Female Patients Using Pyrosequencing Technique.
Gomaa Mogahed S, Hamed Y, Ibrahim Moursy Y, Mahomoud Saied M
Asian Pac J Cancer Prev. 2020; 21(2):431-438.
PMID: 32102521
PMC: 7332123.
DOI: 10.31557/APJCP.2020.21.2.431.
Evidence for an ancient 1 pathogenic variant in inherited breast cancer patients from Senegal.
Ndiaye R, Diop J, Bourdon-Huguenin V, Dem A, Diouf D, Dieng M
NPJ Genom Med. 2020; 5:8.
PMID: 32025337
PMC: 6994613.
DOI: 10.1038/s41525-020-0114-7.
Low Prevalence of the Four Common Colombian Founder Mutations in and in Early-Onset and Familial Afro-Colombian Patients with Breast Cancer.
Vargas E, Torres Lopez D, de Deugd R, Gil F, Nova A, Mora L
Oncologist. 2018; 24(7):e475-e479.
PMID: 30541753
PMC: 6656434.
DOI: 10.1634/theoncologist.2018-0346.
Genetics of breast cancer in African populations: a literature review.
Abbad A, Baba H, Dehbi H, Elmessaoudi-Idrissi M, Elyazghi Z, Abidi O
Glob Health Epidemiol Genom. 2018; 3:e8.
PMID: 30263132
PMC: 6152487.
DOI: 10.1017/gheg.2018.8.
Analyses of the genetic diversity and protein expression variation of the acyl: CoA medium-chain ligases, ACSM2A and ACSM2B.
van der Sluis R
Mol Genet Genomics. 2018; 293(5):1279-1292.
PMID: 29948332
DOI: 10.1007/s00438-018-1460-3.
Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations.
Rebbeck T, Friebel T, Friedman E, Hamann U, Huo D, Kwong A
Hum Mutat. 2018; 39(5):593-620.
PMID: 29446198
PMC: 5903938.
DOI: 10.1002/humu.23406.
Mutations in context: implications of BRCA testing in diverse populations.
Felix G, Zheng Y, Olopade O
Fam Cancer. 2017; 17(4):471-483.
PMID: 28918466
PMC: 5980658.
DOI: 10.1007/s10689-017-0038-2.
Impact of germline and somatic BRCA1/2 mutations: tumor spectrum and detection platforms.
Wu H, Wu X, Liang Z
Gene Ther. 2017; 24(10):601-609.
PMID: 28771233
DOI: 10.1038/gt.2017.73.